VivoSim Labs Inc. has released its annual report for the fiscal year ending March 31, 2025. The company reported an increase in royalty revenue, which rose to $119,000 from $109,000 in the previous year, marking a 9% growth. Other income saw a significant increase, reaching approximately $10.1 million from $0.4 million the previous year. This rise was primarily due to the sale of VivoSim's FXR program for $10.0 million, despite a $0.3 million decrease in net interest income. Looking ahead, VivoSim Labs Inc. plans to focus on providing liver and intestinal toxicology insights using NAM models. The company aims to partner with pharmaceutical and biotech firms across all stages of drug development, helping to mitigate risks and costs associated with bringing therapeutics to market. Additionally, VivoSim will offer bespoke services in investigational toxicology and drug action mechanism elucidation. The company also noted that product revenue, previously linked to the sale of human cells by its former division, Mosaic, will no longer be generated following the cessation of Mosaic's commercial operations in the third quarter of fiscal year 2025.